JP2015517555A - ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 - Google Patents

７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 Download PDF

Info

Publication number
JP2015517555A
JP2015517555A JP2015513182A JP2015513182A JP2015517555A JP 2015517555 A JP2015517555 A JP 2015517555A JP 2015513182 A JP2015513182 A JP 2015513182A JP 2015513182 A JP2015513182 A JP 2015513182A JP 2015517555 A JP2015517555 A JP 2015517555A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
cycloalkyl
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015513182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517555A5 (enExample
Inventor
アンドレア ヴォルカーシュトルファー
アンドレア ヴォルカーシュトルファー
オリヴィエ ソラル
オリヴィエ ソラル
ノルベルト ハンドラー
ノルベルト ハンドラー
ステファン キューザック
ステファン キューザック
ティボー ソーベートル
ティボー ソーベートル
セリーヌ ミショー−シモン
セリーヌ ミショー−シモン
クリストフ モリス
クリストフ モリス
ブルーノ ジェトラン
ブルーノ ジェトラン
ティエリー ランジェ
ティエリー ランジェ
マーク スミス
マーク スミス
ソン−サウ ソ
ソン−サウ ソ
ディルク クラッセン−ホーベン
ディルク クラッセン−ホーベン
ヘルムート ブッシュマン
ヘルムート ブッシュマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical Europaisches Laboratorium fuer Molekularbiologie EMBL
Publication of JP2015517555A publication Critical patent/JP2015517555A/ja
Publication of JP2015517555A5 publication Critical patent/JP2015517555A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015513182A 2012-05-23 2013-05-23 ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 Pending JP2015517555A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650713P 2012-05-23 2012-05-23
US61/650,713 2012-05-23
PCT/EP2013/060633 WO2013174930A2 (en) 2012-05-23 2013-05-23 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (2)

Publication Number Publication Date
JP2015517555A true JP2015517555A (ja) 2015-06-22
JP2015517555A5 JP2015517555A5 (enExample) 2016-07-14

Family

ID=48669865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513182A Pending JP2015517555A (ja) 2012-05-23 2013-05-23 ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用

Country Status (11)

Country Link
US (2) US9434745B2 (enExample)
EP (1) EP2864338B1 (enExample)
JP (1) JP2015517555A (enExample)
KR (1) KR20150009553A (enExample)
CN (1) CN104334563B (enExample)
BR (1) BR112014029016A8 (enExample)
CA (1) CA2874250A1 (enExample)
ES (1) ES2617861T3 (enExample)
MX (1) MX2014014106A (enExample)
RU (1) RU2014143250A (enExample)
WO (1) WO2013174930A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521189A (ja) * 2012-05-23 2015-07-27 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
CN105980386B (zh) 2013-03-13 2021-08-13 基因泰克公司 吡唑并化合物及其用途
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PL3077397T3 (pl) 2013-12-06 2020-04-30 Vertex Pharmaceuticals Inc. Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
CA2953862A1 (en) 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
ES2938877T3 (es) 2015-04-28 2023-04-17 Shionogi & Co Derivados de piridona policíclicos sustituidos y profármacos de los mismos
EP4219508B1 (en) 2015-04-28 2024-06-05 Shionogi & Co., Ltd Substituted polycyclic pyridone derivative and prodrug thereof
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
CR20180356A (es) 2015-12-15 2018-08-22 Shionogi & Co Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza
JP6957535B2 (ja) 2016-06-29 2021-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピリダジノンベースの広域スペクトル抗インフルエンザ阻害剤
NZ791086A (en) 2016-08-10 2025-08-29 Shionogi & Co Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof
JP2020533376A (ja) 2017-09-15 2020-11-19 アドゥロ バイオテック，インク． ピラゾロピリミジノン化合物およびその使用
CN117304133A (zh) * 2023-09-26 2023-12-29 华南农业大学 一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502770A (ja) * 2000-07-12 2004-01-29 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての複素環カルボキシアミド
JP2015521189A (ja) * 2012-05-23 2015-07-27 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
AU4172197A (en) * 1996-09-10 1998-04-02 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
RU2220960C2 (ru) * 1997-12-22 2004-01-10 Фармация Энд Апджон Компани 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе
US20040176366A1 (en) 2002-08-30 2004-09-09 Wathen Michael W Method of preventing or treating atherosclerosis or restenosis
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
TW200716632A (en) 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
EP2412708A4 (en) 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502770A (ja) * 2000-07-12 2004-01-29 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての複素環カルボキシアミド
JP2015521189A (ja) * 2012-05-23 2015-07-27 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521189A (ja) * 2012-05-23 2015-07-27 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体

Also Published As

Publication number Publication date
WO2013174930A3 (en) 2014-01-23
CN104334563A (zh) 2015-02-04
BR112014029016A8 (pt) 2018-01-09
EP2864338B1 (en) 2016-12-14
ES2617861T3 (es) 2017-06-20
CN104334563B (zh) 2017-03-08
WO2013174930A2 (en) 2013-11-28
CA2874250A1 (en) 2013-11-28
EP2864338A2 (en) 2015-04-29
US20130317022A1 (en) 2013-11-28
RU2014143250A (ru) 2016-07-20
BR112014029016A2 (pt) 2017-06-27
MX2014014106A (es) 2015-09-25
HK1205128A1 (en) 2015-12-11
US20160362423A1 (en) 2016-12-15
US9434745B2 (en) 2016-09-06
KR20150009553A (ko) 2015-01-26

Similar Documents

Publication Publication Date Title
CN104507481B (zh) 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物
CN104334563B (zh) 7‑氧代‑噻唑并吡啶碳酸衍生物和它们在治疗、改善或预防病毒疾病中的用途
JP2015524457A (ja) ジヒドロキシピリミジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防における使用
JP6033873B2 (ja) ピリミジン−４−オン誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用
JP6047168B2 (ja) ヘテロアリールヒドロキサム酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用
JP2017521424A (ja) ウイルス疾患の治療、改善又は予防におけるジヒドロピリドピラジン−１，８−ジオン及びそれらの使用
TW201726678A (zh) 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
JP2016508145A (ja) ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用
EP2945945B1 (en) Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017046318A1 (en) Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease
WO2017046362A1 (en) Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
EP3166943A1 (en) Pyridopyrazine compounds and their use in the treatment, amelioration or prevention of influenza
HK1205128B (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017046350A1 (en) Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150120

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150120

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180529